You are viewing: Canada Nuclear Medicine Market analysis
Part of: Nuclear Medicine Market (Global)

The Canada Nuclear Medicine Market was valued at $230.1 Million in 2025 and projected to reach to $402.7 Million by 2030, representing a compound annual growth rate of 11.8%. Canada's nuclear medicine market is positioned for sustained expansion through 2030, driven by an aging demographic requiring advanced diagnostic capabilities and chronic disease management.

Canada Nuclear Medicine Market Trends and Insights

  • This 11.8% compound annual growth rate reflects Canada's advancing healthcare infrastructure and increasing adoption of diagnostic imaging technologies.
  • Canada's aging population and rising prevalence of chronic diseases are driving demand for nuclear medicine procedures, particularly in oncology and cardiology applications. The Canadian market benefits from strong regulatory frameworks, established reimbursement pathways, and significant investment in medical imaging facilities across provinces.
  • Canada's healthcare system's emphasis on early disease detection and personalized medicine is accelerating nuclear medicine adoption.
  • Between 2025 and 2030, Canada is expected to see expanded radiopharmaceutical production capacity and enhanced access to diagnostic imaging in both urban and rural healthcare settings. Canada's position within North America positions it as a key market for nuclear medicine innovation and clinical applications.
  • The country's commitment to healthcare modernization and integration of advanced diagnostic technologies supports sustained market expansion through 2030..

Key Market Statistics

  • CAGR (2025-2030) 11.8% CAGR
  • Market Size, 2025 ~USD 230.1 Million
  • Forecast, 2030 ~USD 402.7 Million
  • Country Canada

Canada Nuclear Medicine Market Overview

Market Valuation Growth :

Canada's nuclear medicine market is valued at $230.1 million in 2025, with projections reaching $402.7 million by 2030, representing a robust 11.8% CAGR driven by healthcare modernization and diagnostic advancement.

Aging Population Dynamics :

Canada's demographic shift toward an older population is significantly increasing demand for nuclear medicine diagnostics, particularly for oncology, cardiology, and neurology applications where early detection is critical.

Healthcare Infrastructure Investment :

Canadian provinces are investing heavily in advanced imaging technologies and nuclear medicine facilities, supported by government healthcare funding and private sector expansion across major metropolitan centers.

Chronic Disease Prevalence :

Rising incidence of cancer, cardiovascular disease, and neurological disorders in Canada is accelerating adoption of nuclear medicine imaging for diagnosis, staging, and treatment monitoring across healthcare systems.

Canada Nuclear Medicine Market Dynamics

  • Provincial healthcare systems are increasingly integrating nuclear medicine into standard care protocols, supported by technological innovations in imaging equipment and radiopharmaceuticals.
  • The market benefits from Canada's universal healthcare system, which ensures broad patient access and consistent demand for diagnostic services. Key growth catalysts include rising cancer incidence, cardiovascular disease prevalence, and neurological disorder diagnoses across the Canadian population.
  • Investment in healthcare infrastructure modernization, coupled with growing physician adoption of nuclear medicine for precision diagnostics, will sustain the 11.8% CAGR through 2030.
  • Regulatory support and reimbursement policies further strengthen market fundamentals for equipment manufacturers, radiopharmaceutical suppliers, and imaging service providers operating in Canada..

Related Ecosystem

Pharmaceuticals

Top Technologies
  • Bioreactors
  • Analytical Testing
  • Bioanalytical Testing Services
  • Cell Counters
  • Data Management Services
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • SANOFI
  • NOVARTIS
  • Pfizer Inc.

    Key Takeaways

    • Canada's nuclear medicine market will grow from $230.1M (2025) to $402.7M (2030) at an 11.8% CAGR.
    • Canada's aging demographic and chronic disease prevalence are primary drivers of nuclear medicine demand.
    • Canada's robust regulatory environment and provincial healthcare integration support market expansion.
    • Canada is positioned as a North American hub for radiopharmaceutical innovation and clinical deployment.

    Nuclear Medicine Market Report Scope

    Report Metric Details
    Base Year 2025
    Fastest Growing Segment THERAPEUTIC NUCLEAR MEDICINE (Type)
    Forecast Period 2025–2039
    Growth Rate CAGR of 15.1% from 2025 to 2039
    Largest Segment DIAGNOSTIC PROCEDURES (Procedure)
    Market Size Base Year (Billions) ~USD 10.4 (2025)
    Revenue Forecast (Billions) ~USD 21.01 (2039)
    Segments Covered Type, Application, Procedure, End User

    Canada Nuclear Medicine Market Report Segmentation

    4 segment dimensions are covered across the global market.

    By Type

    • Alpha Emitters
    • Beta Emitters
    • Bone Metastasis
    • Bone Scans
    • Brachytherapy Isotopes
    • Cardiology
    • Cs-131
    • Diagnostic Nuclear Medicine
    • Endocrine Tumors
    • F-18
    • Ga-67
    • I-123
    • I-125
    • I-131
    • Ir-192
    • Lu-177
    • Lymphoma
    • Neurology
    • Oncology
    • Other Beta Emitters
    • Other Brachytherapy Isotopes
    • Other Pet Applications
    • Other Pet Radiopharmaceuticals
    • Other Spect Applications
    • Other Spect Radiopharmaceuticals
    • Other Therapeutic Applications
    • Pd-103
    • Pet Applications
    • Pet Procedures
    • Pet Radiopharmaceuticals
    • Pulmonary Scans
    • Ra-223
    • Rb-82
    • Sm-153
    • Spect Applications
    • Spect Procedures
    • Spect Radiopharmaceuticals
    • Tc-99M
    • Therapeutic Nuclear Medicine
    • Thyroid
    • Tl-201
    • Y-90

    By Application

    • Diagnostic Applications
    • Therapeutic Applications

    By Procedure

    • Diagnostic Procedures
    • Therapeutic Procedures

    By End User

    • Academic & Research Institutes
    • Diagnostic & Imaging Centers
    • Hospitals
    • Other End Users

    Target Audience

    • Medical Device Manufacturers : Nuclear medicine equipment manufacturers need Canada-specific market data to assess market size, growth potential, competitive positioning, and regional demand for imaging systems, cyclotrons, and diagnostic equipment across Canadian healthcare facilities.
    • Radiopharmaceutical Companies : Pharmaceutical and radiopharmaceutical suppliers require detailed Canadian market insights to understand demand for diagnostic agents, optimize distribution networks, navigate Health Canada regulations, and forecast revenue opportunities in this growing segment.
    • Healthcare Facility Operators : Hospital networks, diagnostic imaging centers, and private clinics in Canada need market intelligence to justify capital investments in nuclear medicine infrastructure, benchmark operational performance, and plan service expansion strategies.
    • Investment & Private Equity Firms : Investors evaluating healthcare opportunities in Canada require comprehensive market analysis to assess investment returns, identify acquisition targets, evaluate growth potential, and make informed decisions on nuclear medicine sector investments.
    • Healthcare Consultants & Policy Makers : Healthcare consultants and government agencies need Canada-specific market data to inform policy decisions, healthcare planning, resource allocation, and strategic initiatives related to diagnostic imaging and nuclear medicine service delivery.

    Key Companies in the Canada Nuclear Medicine Market

    CompanyHQOwnershipStrongest segments
    BIOMERIEUX S.A.FrancePublic CompanySPECT,PET,Beta Emitters,
    CARL ZEISS AGGermanyPublic CompanyPET (F-18),SPECT (Tc-99m),
    ATS AUTOMATION TOOLING SYSTEMS INCCanadaPublic CompanySPECT,PET,Brachytherapy,
    BRUKER CORPORATIONUnited StatesPublic CompanyPET,SPECT,Beta Emitters,
    SHIMADZU CORPORATIONJapanPublic CompanyPET (F-18),SPECT (Tc-99m),Alpha Emitters,
    VARIAN MEDICAL SYSTEMS, INCUnited StatesPrivate CompanyBrachytherapy,Linear Accelerators,Software Solutions,
    LEONI AGGermanyPrivate CompanyPET Systems,SPECT Systems,Beta Emitters,
    PFIZERUnited StatesPublic CompanyPET (F-18),Beta Emitters (Y-90, Lu-177),SPECT (Tc-99m),
    ELEKTA ABSwedenPublic CompanyBrachytherapy,Linear Accelerators,Stereotactic Radiosurgery,
    NOVARTIS AGSwitzerlandPublic CompanyBeta Emitters,SPECT,Alpha Emitters,
    LANTHEUS HOLDINGS, INC.United StatesPublic CompanyPET,SPECT,Beta Emitters,
    GE HEALTHCAREUnited StatesPublic CompanySPECT,PET,Brachytherapy,
    TELIX PHARMACEUTICALS LIMITEDAustraliaPublic CompanyPET Imaging,Therapeutics,Manufacturing Solutions,
    SIEMENS HEALTHINEERSGermanyPublic CompanyPET,SPECT,Beta Emitters,
    CHINA ISOTOPE & RADIATION CORPORATIONChinaPublic CompanySPECT,PET,Beta Emitters,
    BAYER AGGermanyPublic CompanySPECT,PET,Alpha Emitters,
    CARDINAL HEALTHUnited StatesPublic CompanySPECT,PET,Beta Emitters,

    BIOMERIEUX S.A.

    bioMérieux S.A. is a French public company founded in 1963 that employs 14,894 people. The company operates in the diagnostics and life sciences sector.

    CARL ZEISS AG

    Carl Zeiss AG is a German public company founded in 1846 with 5,798 employees. The company specializes in optical systems and precision instruments.

    ATS AUTOMATION TOOLING SYSTEMS INC

    ATS Automation Tooling Systems Inc. is a Canadian public company founded in 1978 with 7,000 employees. The company provides automation and tooling solutions.

    BRUKER CORPORATION

    Bruker Corporation is a United States public company founded in 1960 with 11,085 employees. The company manufactures scientific instruments and analytical solutions.

    SHIMADZU CORPORATION

    Shimadzu Corporation is a Japanese public company founded in 1875 with 14,649 employees. The company manufactures analytical and scientific instruments.

    VARIAN MEDICAL SYSTEMS, INC

    Varian Medical Systems, Inc. is a United States private company founded in 1948 with 10,000 employees. The company specializes in medical devices and radiation oncology solutions.

    LEONI AG

    Leoni AG is a German private company founded in 1569 with 95,090 employees. The company manufactures cables, wiring systems, and related products.

    PFIZER

    Pfizer is a United States public company founded in 1849 with 75,000 employees. The company is a major pharmaceutical manufacturer and developer.

    ELEKTA AB

    Elekta AB is a Swedish public company founded in 1972 with 4,353 employees. The company specializes in radiation therapy and radiosurgery solutions.

    NOVARTIS AG

    Novartis AG is a Swiss public company founded in 1996 with 75,267 employees. The company is a leading pharmaceutical and healthcare company.

    LANTHEUS HOLDINGS, INC.

    Lantheus Holdings, Inc. is a United States public company founded in 1956 with 1,193 employees. The company develops diagnostic imaging agents and radiopharmaceuticals.

    GE HEALTHCARE

    GE Healthcare is a United States public company founded in 2022 with 54,000 employees. The company provides medical imaging, diagnostics, and healthcare IT solutions.

    TELIX PHARMACEUTICALS LIMITED

    Telix Pharmaceuticals Limited is an Australian public company founded in 2015 with 1,152 employees. The company develops diagnostic and therapeutic radiopharmaceuticals.

    SIEMENS HEALTHINEERS

    Siemens Healthineers is a German public company founded in 1896 with 72,369 employees. The company provides medical imaging, diagnostics, and healthcare solutions.

    CHINA ISOTOPE & RADIATION CORPORATION

    China Isotope & Radiation Corporation is a Chinese public company founded in 1983 with 3,578 employees. The company operates in the isotope and radiation sector.

    BAYER AG

    Bayer AG is a German public company founded in 1863 with 87,757 employees. The company operates in pharmaceuticals, crop science, and consumer health.

    CARDINAL HEALTH

    Cardinal Health is a United States public company founded in 1979 with 55,392 employees. The company is a healthcare services and products distributor.

    Reasons to Buy this Report

    • Market Size & Growth Validation : Obtain precise valuation data for Canada's nuclear medicine market ($230.1M in 2025) with verified 11.8% CAGR projections through 2030, enabling accurate financial forecasting and investment decision-making specific to the Canadian market.
    • Competitive Landscape Intelligence : Understand Canada-specific competitive dynamics, key market players, and regional market share distribution to identify partnership opportunities, acquisition targets, and competitive positioning strategies within Canadian healthcare systems.
    • Regulatory & Reimbursement Insights : Access detailed analysis of Canadian provincial healthcare policies, reimbursement frameworks, and regulatory requirements governing nuclear medicine services, ensuring compliance and optimizing market entry strategies.
    • Demographic & Clinical Demand Drivers : Leverage Canada-specific epidemiological data on aging population, cancer prevalence, and chronic disease incidence to forecast demand for nuclear medicine diagnostics and align product development with clinical needs.
    • Regional Growth Opportunity Assessment : Identify high-growth provinces and metropolitan markets within Canada, assess infrastructure gaps, and prioritize resource allocation for facility expansion, equipment deployment, and service offerings in underserved regions.

    Frequently asked questions

    What is the current size of Canada's nuclear medicine market?

    Canada's nuclear medicine market is valued at $230.1 million in 2025 and is projected to reach $402.7 million by 2030.

    What is the growth rate of Canada's nuclear medicine market?

    Canada's nuclear medicine market is growing at a compound annual growth rate (CAGR) of 11.8% from 2025 to 2030.

    What factors are driving growth in Canada's nuclear medicine market?

    Canada's nuclear medicine market growth is driven by an aging population, rising chronic disease prevalence, advanced healthcare infrastructure, strong regulatory frameworks, and increased adoption of diagnostic imaging technologies.

    Which medical applications dominate Canada's nuclear medicine market?

    Oncology and cardiology applications represent the largest segments in Canada's nuclear medicine market, supported by early disease detection initiatives and personalized medicine approaches.

    How does Canada's healthcare system support nuclear medicine expansion?

    Canada's provincial healthcare systems provide established reimbursement pathways, regulatory oversight, and investment in medical imaging facilities that facilitate nuclear medicine adoption and radiopharmaceutical production capacity expansion.

    RESEARCH METHODOLOGY

    This study involved four major activities in estimating the size of the nuclear medicine market. Exhaustive secondary research was done to collect information on the market, peer market, and parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across value chains through primary research. The bottom-up approach was employed to estimate the overall market size. After that, market breakdown and data triangulation were used to estimate the market size of segments and sub-segments.

    Secondary Research

    The secondary research process involved the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, and SEC filings of companies. Some non-exclusive secondary sources include the Organisation for Economic Co-operation and Development (OECD), European Association of Nuclear Medicine (EANM), National Institutes of Health (NIH), World Nuclear Association (WNA), International Atomic Energy Agency (IAEA), Nuclear Regulatory Commission (NRC), Society of Nuclear Medicine and Molecular Imaging (SNMMI), Nuclear Energy Agency (NEA), Australian Nuclear Science and Technology Organisation (ANSTO), Annual Reports, SEC Filings, Investor Presentations, Journals, Publications from Government Sources and Professional Associations, Expert Interviews, and MarketsandMarkets Analysis.

    Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the clinical decision support system market. It was also used to obtain important information about the key players and market classification and segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

    Primary Research

    In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations operating in the clinical decision support system market. The primary sources from the demand side included industry experts, consultants, healthcare providers, hospital administration, and government bodies. Primary research was conducted to validate the market segmentation, identify key players in the market, and gather insights on key industry trends and key market dynamics.

    Breakdown of Primary Interviews

    Nuclear Medicine Market Size, and Share

    Note 1: Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.

    Note 2: Tiers of companies are defined on the basis of their total revenue in 2022; Tier 1: >USD 1 billion, Tier 2: USD 500 million to USD 1 billion, and Tier 3: <USD 500 million.

    To know about the assumptions considered for the study, download the pdf brochure

    Report Metric

    Details

    Siemens Healthineers

    Sr.Sales Manager

    Curium

    General Manager

    Cardinal Health

    Product Sales Specialist

    Market Size Estimation

    Both top-down and bottom-up approaches were used to estimate and validate the total size of the nuclear medicine market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

    • The key players in the industry and markets have been identified through extensive secondary research
    • The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research processes
    • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

    Data Triangulation

    After arriving at the overall market size—using the market size estimation processes as explained above—the market was split into several segments and sub-segments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, the data triangulation, and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides, in the provider, payer, and other industries.

    Market Definition

    Radiopharmaceuticals are drugs that contain radionuclide-emitting ionizing radiation and are used in nuclear imaging to diagnose and treat diseases. The nuclear medicine market is bifurcated into diagnostic and therapeutic segments. Radiopharmaceuticals in the diagnostics market are categorized as SPECT and PET, while radiopharmaceuticals in the therapeutics market are categorized as beta emitters, alpha emitters, and brachytherapy isotopes.

    Key Stakeholders

    • Senior Management
    • Finance/Procurement Department
    • R&D Department

    Report Objectives

    • To define, describe, and forecast the nuclear medicine market on the basis of type, application, procedure volume,end user, and region
    • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
    • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
    • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
    • To forecast the size of the market segments with respect to four main regions—North America, Europe, the Asia Pacific, and the Rest of the World (RoW)
    • To profile the key players and comprehensively analyze their market shares and core competencies
    • To track and analyze competitive developments such as partnerships, collaborations, agreements, product approval & enhancements, expansions, and acquisitions in the nuclear medicine market

    Available Customizations

    MarketsandMarkets offers the following customizations for this market report:

    • Additional country-level analysis of the nuclear medicine market.
    • Profiling of additional market players (up to 3)

    Get the Full Nuclear Medicine Market Report

    Full forecast, segment splits, and company analysis for all Nuclear Medicine Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status